Of the top candidate genes, KCTD10, ACTR10, RIF1, TECB1, PCMT1, RBM8A, PSMD14 and FAM32A were selected for clinical validation by comparing the mRNA levels in paired patient specimens, including primary serous ovarian cancer and metastatic tumor tissues. This evidence concerns the gene PCMT1 and metastatic neoplasm.